References
- Biologics Price Competition and Innovation Act. Codified at 42 U.S.C. § 262.
- Schellekens H. Biosimilar therapeutics – what do we need to consider? NDT Plus. 2009;2(Suppl 1):i27–i36. at i28
- Food & Drug Admin. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Silver Spring (MD): US Food and Drug Administration; 2012. at 9.
- Food & Drug Admin. Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product. Silver Spring (MD): US Food and Drug Administration; 2012. at 9.
- Food & Drug Admin. Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product. Silver Spring (MD): US Food and Drug Administration; 2012. at 12.
- Biologics Price Competition and Innovation Act. 42 U.S.C. § 262(i)(2)(A).
- Food & Drug Admin. Guidance for industry on biosimilars: Q & A as regarding implementation of the BPCI Act of 2009. Silver Spring (MD): US Food and Drug Administration; 2009. at 4-5.
- Food & Drug Admin. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Silver Spring (MD): US Food and Drug Administration; 2012. at 8.
- Biologics Price Competition and Innovation Act. 42 U.S.C. § 262(k)(2)(A)(i)(II-IV)
- Food & Drug Admin. Guidance for industry on biosimilars: Q & A as regarding implementation of the BPCI act of 2009. Silver Spring (MD): US Food and Drug Administration; 2009. at 5.
- Food & Drug Admin. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Silver Spring (MD): US Food and Drug Administration; 2012. at 17.
- United States Code Title 21 – Food and Drugs. 21 U.S.C. § 355(j)(2)(A).
- Biologics Price Competition and Innovation Act. 42 U.S.C. § 262(i)(2)(A).
- United States Code Title 35 - Patents. 35 U.S. C. § 102(a).
- United States Code Title 35 - Patents. 35 U.S. Code § 103.
- Manual of Patent Examination Procedure. MPEP § 716.02(A).
- Darrow J. The patentability of enantiomers: implications for the pharmaceutical industry. Stan Tech L Rev 2. at para 46. 2007.
- Brenner v. Manson. 383 U.S. 519. 1966.
- Food and Drug Administration. FDA Approves first biosimilar product Zarxio. FDA News Release. [ cited 2015 Mar 6]. Available from: <www.fda.gov>.
- Stable aqueous g-csf formulations. World Patent No. WO2008122415 A1.
- Long-term storage of non-glycosylated recombinant Human G-CSF. US Patent No. US8449873 B2.
- Method for producing a recombinant protein of interest. US Patent No. US20140170701 A1 at 9.
- Committee for Medicinal Products for Human Use. Bemfola Assessment Report. EMA/65507/2013 rev.1. at 74.
- Committee for Medicinal Products for Human Use. Bemfola Assessment Report. EMA/65507/2013 rev.1. at 10.
- Committee for Medicinal Products for Human Use. Bemfola Assessment Report. EMA/65507/2013 rev.1. at 10.
- Thelwell C, Longstaff C. Biosimilars: the process is the product. J Thromb Haemostasis. 2014;12:1229–1233.
- A method for producing n-terminal methionine free polypeptides in microbial host cells. World Patent Application No. 2008065673 A1.
- Committee for Medicinal Products for Human Use. Nivestim Assessment Report. EMEA/H/C/001142 at 9.
- European Medicines Agency. Nivestim Summary of Product Characteristics at 17.
- Amgen Canada Inc. Neupogen Product Monograph. 2014. Available from: <https://www.amgen.ca/Neupogen_PM.pdf> at 28.
- Glycosylation analogs of erythropoietin. US Patent No. 7217689 B1.